New Bioorthogonal System Boosts Cancer Visualization in Surgery
Researchers have developed an improved method for visualizing cancer cells during surgery, addressing limitations of existing techniques that can result in healthy tissue activation or missed cancer cells. This novel system utilizes a specialized enzyme delivered to tumors and a fluorescent probe that activates only in the enzyme's presence.
Precision Activation for Clearer Vision
The new method tackles a significant issue with older diagnostic tools. Ryosuke Kojima, Associate Professor at the University of Tokyo's Laboratory of Chemical Biology and Molecular Imaging, explained that "older probes often activate healthy tissue."
The newly developed bioorthogonal dye probe is designed to remain inactive unless it encounters its matching engineered enzyme.
This enzyme was meticulously developed through directed evolution to activate the probe sufficiently within living organisms. Professor Kojima, Professor Yasuteru Urano, and their team created a fluorescent probe resistant to activation by natural enzymes in the body. This probe is specifically paired with a tailored reporter enzyme designed to switch it on, localizing fluorescence precisely where the enzyme is delivered.
Promising Results in Mouse Trials
In initial tests, the system demonstrated significant efficacy. When applied to mice bearing peritoneal cancer, the engineered enzyme successfully reached abdominal wall tumors. Subsequent application of the fluorescent probe resulted in clear illumination of these cancerous areas.
This system enabled the visualization of millimeter-sized tumor lesions with minimal background noise, achieving a level of contrast that could be highly beneficial during surgical procedures.
Future Applications and Hurdles
Kojima indicated that, in the short term, this system holds promise as a valuable research tool. In the long term, it may significantly assist surgeons in more completely removing tumors by clearly identifying cancer cells during operations.
A significant challenge for clinical application, however, is ensuring the engineered enzyme does not provoke an immune response in patients.
The system is potentially adaptable to various cancer types beyond peritoneal cancer, as many cancers possess corresponding antigens. By modifying the tumor-targeting component, the enzyme-probe pair could be redirected to other forms of cancer.
Beyond Visualization: Targeted Drug Delivery
Additionally, this research could inform highly targeted drug delivery, where cancer-fighting medications are directed specifically to tumor sites. However, trials are currently limited to mice, and further research is necessary before considering human trials.